Urinary Bladder Neoplasms Clinical Trial
— EV-103Official title:
A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer
Verified date | October 2023 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.
Status | Active, not recruiting |
Enrollment | 348 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Locally advanced or metastatic urothelial cancer (la/mUC) - Cohorts A, B, D, E, F, G and K. - Histologically documented la/mUC, including squamous differentiation or mixed cell types. - An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2: Participants with ECOG performance status of 2 must meet the following additional criteria: hemoglobin =10 g/dL, GFR =50 mL/min, may not have NYHA Class III heart failure. - Eligible for pembrolizumab (Dose-escalation cohorts, Cohorts A, B, G and K Combination Arm). - Dose-escalation cohorts: Ineligible for first-line cisplatin-based chemotherapy and no prior treatment for la/mUC, or have disease progression following at least 1 platinum-containing treatment. - Cohort A: Ineligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. - Cohort B: Must have disease progression during/following treatment with at least 1 platinum-containing regimen for la/mUC or disease recurrence. - Cohort D: Eligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. - Cohort E: Ineligible for cisplatin-based chemotherapy, eligible for carboplatin, and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. - Cohort F: Ineligible for platinum-based chemotherapy, or disease progression during/following at least 1 prior treatment for la/mUC. Eligible for gemcitabine. - Cohort G: Eligible for platinum-based chemotherapy (either cisplatin or carboplatin) and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. - Cohort K: Ineligible for cisplatin-based chemotherapy due to at least 1 of the following: Glomerular filtration rate (GFR) <60 mL/min and =30 mL/min, ECOG performance status of 2, NCI CTCAE Version 4.03 Grade =2 hearing loss, New York Heart Association (NYHA) Class III heart failure. No prior systemic treatment for locally advanced or metastatic disease. No adjuvant/neoadjuvant platinum-based therapy within 12 months prior to randomization. - Muscle Invasive Bladder Cancer (MIBC)- Cohorts H, J and L. - Histologically confirmed MIBC with predominant >50% urothelial histology: Cohorts H and J: Clinical stage cT2-T4aN0M0; Cohort L: Clinical stage cT2-T4aN0M0 or cT1-T4aN1M0: Participants with pT1 disease are eligible only if they have N1 disease on imaging. Mixed cell types are eligible if urothelial cancer is predominant (>50%); Participants with plasmacytoid and/or neuroendocrine tumors are ineligible regardless of component percentage. Urothelial tumors not originating in the bladder (eg, upper tract tumors, urethral tumors) are ineligible. - Must be cisplatin-ineligible. - Cohort-specific eligibility: Cohort J, H, and L: No prior systemic treatment, chemoradiation, or radiation therapy for MIBC. May have received prior intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy for non-MIBC; Cohort J: Eligible for pembrolizumab. - ECOG performance status of 0, 1, or 2. - Anticipated life expectancy of =3 months. - Tumor samples with an associated pathology report from the diagnostic transurethral resection of a bladder tumor done 90 days prior to the first dose of study treatment must be available prior to enrollment and determined to be sufficient for pathology review and biomarker analysis. - Participants must be deemed eligible for RC+PLND. Exclusion Criteria: - la/mUC - Cohorts A, B, D, E, F, G, and K - Received any prior treatment with a PD-1 inhibitor, PD-L1 inhibitor, or PD-L2 inhibitor, except Cohort F. - Received any prior treatment with stimulatory or co-inhibitory T-cell receptor agents, such as CD137 agonists, OX-40 agonists, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (except Cohort F). - Ongoing sensory or motor neuropathy Grade 2 or higher. - Active central nervous system (CNS) metastases. - Ongoing clinically significant toxicity (Grade 2 or greater) associated with prior treatment (including radiotherapy or surgery). - Conditions requiring high doses of steroids or other immunosuppressive medications. - Prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs). - Uncontrolled diabetes mellitus. - MIBC - Cohorts H, J, and L - Received prior systemic treatment, chemoradiation, and/or radiation therapy of muscle invasive bladder cancer. - Received any prior treatment with a CPI. - Received any prior treatment with stimulatory or co-inhibitory T-cell receptor agents, such as CD137 agonists, CTLA-4 inhibitors, or OX-40 agonists. - For participants in Cohort H, evidence of nodal disease on imaging. For participants in Cohort L, =N2 nodal disease on imaging. - Participant has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC. - Ongoing sensory or motor neuropathy Grade 2 or higher. - Conditions requiring high doses of steroids or other immunosuppressive medications. - Prior treatment with enfortumab vedotin or other MMAE-based ADCs for urothelial cancer. - Participants with a history of another invasive malignancy within 3 years before first dose of study drug. |
Country | Name | City | State |
---|---|---|---|
Canada | Site CA11008 | East Brampton | Ontario |
Canada | Site CA11011 | Kingston | Ontario |
Canada | Site CA11005 | Montreal | Quebec |
Canada | Site CA11013 | Montreal | Quebec |
Canada | Site CA11002 | Sherbrooke | Quebec |
Canada | Site CA11001 | Toronto | Ontario |
France | Site FR33008 | Bordeaux | |
France | Site FR33005 | Dijon | |
France | Site FR33003 | Lyon | |
France | Site FR33004 | Marseilles | |
France | Site FR33010 | Moselle | |
France | Site FR33002 | Nice Cedex | |
France | Site FR33006 | Pierre-Benite | |
France | Site FR33001 | Strasbourg | |
Italy | Site IT39002 | Terni | |
Puerto Rico | Site PR78701 | Rio Piedras | |
Spain | Site ES34006 | Barcelona | |
Spain | Site ES34001 | Madrid | |
Spain | Site ES34008 | Madrid | |
Spain | Site ES34012 | Madrid | |
Spain | Site ES34007 | Pamplona | |
Spain | Site ES34005 | Sabadell | |
Spain | Site ES34004 | Santander | |
United States | New York Oncology Hematology, P.C. | Albany | New York |
United States | University of New Mexico Cancer Center | Albuquerque | New Mexico |
United States | Alaska Urological Institute | Anchorage | Alaska |
United States | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan |
United States | Piedmont Cancer Institute | Atlanta | Georgia |
United States | Winship Cancer Institute / Emory University School of Medicine | Atlanta | Georgia |
United States | Rocky Mountain Cancer Centers - Aurora | Aurora | Colorado |
United States | University of Colorado Hospital / University of Colorado | Aurora | Colorado |
United States | Memorial Sloan Kettering Cancer Center - Basking Ridge | Basking Ridge | New Jersey |
United States | Tower Hematology Oncology Medical Group | Beverly Hills | California |
United States | Boca Raton Regional Hospital / Lynn Cancer Institute | Boca Raton | Florida |
United States | CMOH Broomall | Broomall | Pennsylvania |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Gabrail Cancer Center Research, LLC | Canton | Ohio |
United States | UNC Lineberger Comprehensive Cancer Center / University of North Carolina | Chapel Hill | North Carolina |
United States | Medical University of South Carolina/Hollings Cancer Center | Charleston | South Carolina |
United States | Levine Cancer Institute | Charlotte | North Carolina |
United States | University of Virginia | Charlottesville | Virginia |
United States | Sarah Cannon Research Institute | Chattanooga | Tennessee |
United States | University of Chicago Medical Center | Chicago | Illinois |
United States | Case Western Reserve University / University Hospitals Case Medical Center | Cleveland | Ohio |
United States | Memorial Sloan Kettering Cancer Center - Commack | Commack | New York |
United States | Decatur Memorial Hospital - Illinois | Decatur | Illinois |
United States | Northwestern Medicine Cancer Center - Kishwaukee / Kishwaukee Cancer Center | DeKalb | Illinois |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Southcoast Centers for Cancer Care - Fairhaven Site | Fairhaven | Massachusetts |
United States | Highlands Oncology Group | Fayetteville | Arkansas |
United States | Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center | Fort Lauderdale | Florida |
United States | Texas Oncology - Fort Worth Cancer Center | Fort Worth | Texas |
United States | Northwestern Medicine Cancer Center Delnor | Geneva | Illinois |
United States | Banner MD Anderson Cancer Center | Gilbert | Arizona |
United States | Saint Francis Hospital Cancer Center | Greenville | South Carolina |
United States | Vidant Medical Center | Greenville | North Carolina |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Memorial Sloan Kettering Cancer Center - Westchester | Harrison | New York |
United States | Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Mayo Clinic Florida | Jacksonville | Florida |
United States | UC San Diego / Moores Cancer Center | La Jolla | California |
United States | Northwell Cancer Center / Monter Cancer Center | Lake Success | New York |
United States | McLaren Greater Lansing Hospital | Lansing | Michigan |
United States | OptumCare Cancer Center | Las Vegas | Nevada |
United States | Nebraska Hematology Oncology P.C. | Lincoln | Nebraska |
United States | Cardinal Bernardin Cancer Center / Loyola University Medical Center | Maywood | Illinois |
United States | University of Miami | Miami | Florida |
United States | Memorial Sloan Kettering Cancer Center - Monmouth | Middletown | New Jersey |
United States | Medical College of Wisconsin (Milwaukee) | Milwaukee | Wisconsin |
United States | NYU Winthrop Hospital | Mineola | New York |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | Memorial Sloan Kettering Cancer Center - Bergen | Montvale | New Jersey |
United States | Carolina Urologic Research Center | Myrtle Beach | South Carolina |
United States | Tennessee Oncology / Sarah Cannon Research Institute | Nashville | Tennessee |
United States | Yale Cancer Center | New Haven | Connecticut |
United States | Ochsner Clinic Foundation | New Orleans | Louisiana |
United States | Tulane University Hospital and Clinic | New Orleans | Louisiana |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | New York University (NYU) Cancer Institute | New York | New York |
United States | Weill Cornell Medical College | New York | New York |
United States | Virginia Oncology Associates - Norfolk | Norfolk | Virginia |
United States | Eastern CT Hematology and Oncology Associates | Norwich | Connecticut |
United States | University of California Irvine - Newport | Orange | California |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Mayo Clinic Arizona | Phoenix | Arizona |
United States | Allegheny General Hospital | Pittsburgh | Pennsylvania |
United States | University of Rochester Medical Center | Rochester | New York |
United States | University of California, Davis Comprehensive Cancer Center | Sacramento | California |
United States | Washington University School of Medicine - Siteman Cancer Center | Saint Louis | Missouri |
United States | Utah Cancer Specialists | Salt Lake City | Utah |
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
United States | University of California at San Francisco | San Francisco | California |
United States | Saint Joseph Heritage Medical Group | Santa Rosa | California |
United States | Maryland Oncology Hematology, P.A. | Silver Spring | Maryland |
United States | Medical Oncology Associates | Spokane | Washington |
United States | Stanford Cancer Center / Blood & Marrow Transplant Program | Stanford | California |
United States | Toledo Clinic Cancer Center | Toledo | Ohio |
United States | Arizona Oncology Associates, PC - HOPE | Tucson | Arizona |
United States | Texas Oncology - Tyler | Tyler | Texas |
United States | Memorial Sloan Kettering Cancer Center - Nassau | Uniondale | New York |
United States | Northwestern Medicine Cancer Center - Warrenville / Central DuPage Hospital - Cancer Care | Warrenville | Illinois |
United States | Georgetown University Medical Center | Washington | District of Columbia |
United States | University of Kansas Cancer Center | Westwood | Kansas |
United States | Kaiser Permanente Southern California | Woodland Hills | California |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Global Development, Inc. | Merck Sharp & Dohme LLC, Seagen Inc. |
United States, Canada, France, Italy, Puerto Rico, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only) | Descriptive statistics will be used to summarize results. | Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated. | |
Primary | Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only) | Descriptive statistics will be used to summarize results. | Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated. | |
Primary | Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only) | The proportion of patients with confirmed complete response (CR) or partial response (PR) according to RECIST 1.1 | Up to 3 years | |
Primary | Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only) | The proportion of patients with absence of viable tumor tissue at the time of radical cystectomy. | Up to approximately 5 months | |
Secondary | Incidence of dose-limiting toxicity (DLT) | Incidence of DLTs (dose-escalation expansion Cohorts D, E, F, and the first 6 patients of Cohort G). | 21 days | |
Secondary | Confirmed ORR by investigator assessment according to RECIST 1.1 (la/mUC cohorts only) | The proportion of patients with confirmed CR or PR according to RECIST 1.1. | Up to 3 years | |
Secondary | Confirmed ORR by BICR according to RECIST 1.1 (Dose escalation and Cohort A only) | The proportion of patients with confirmed CR or PR according to RECIST 1.1 | Up to 3 years | |
Secondary | Confirmed ORR by investigator assessment per the modified RECIST 1.1 for immune-based therapeutics (iRECIST) (Dose escalation and Part 1-3 cohorts with pembrolizumab only) | The proportion of patients with confirmed CR or PR according to iRECIST. | Up to 3 years | |
Secondary | Disease control rate (DCR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only) | Proportion of patients with CR, PR, or stable disease (SD) according to RECIST 1.1. | Up to 5 years | |
Secondary | DCR by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only) | Proportion of patients with CR, PR, or stable disease (SD) according to RECIST 1.1 | Up to 3 years | |
Secondary | DCR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts using pembrolizumab only) | Proportion of patients with CR, PR, or SD according to iRECIST. | Up to 3 years | |
Secondary | Duration of response (DOR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only) | The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD per RECIST 1.1) or to death due to any cause, whichever comes first. | Up to 5 years | |
Secondary | DOR by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only) | The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD per RECIST 1.1 or to death due to any cause, whichever comes first | Up to 5 years | |
Secondary | DOR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only) | The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD per iRECIST or to death due to any cause, whichever comes first. | Up to 5 years | |
Secondary | Progression free survival on study therapy (PFS) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only) | The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1) on or following study therapy, or to death due to any cause, whichever comes first. | Up to 5 years | |
Secondary | PFS by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only) | The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1) on or following study therapy, or to death due to any cause, whichever comes first | Up to 5 years | |
Secondary | PFS by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only) | The time from start of study treatment to first documentation of objective tumor progression (PD per iRECIST) on or following study therapy, or to death due to any cause, whichever comes first. | Up to 5 years | |
Secondary | Event-free (EFS) on study therapy by BICR (Cohort L only) | The time from the start of study treatment to the first occurrence of any of the following events: (1) Radiographic disease progression precluding a curative intent surgery as assessed by BICR prior to RC+PLND. (2) Failure to undergo RC+PLND for participants with residual muscle-invasive disease and/or any radiographic disease present. (3) Gross residual disease left behind at time of RC+PLND. (4) Local or distant recurrence post-RC as assessed by CT or MRI and/or biopsy. (5) Death from any cause. | Up to 3 years | |
Secondary | Event-free (EFS) on study therapy by investigator assessment (MIBC cohorts only) | The time from the start of study treatment to the first occurrence of any of the following events: (1) Radiographic disease progression precluding a curative intent surgery as assessed by BICR prior to RC+PLND. (2) Failure to undergo RC+PLND for participants with residual muscle-invasive disease and/or any radiographic disease present. (3) Gross residual disease left behind at time of RC+PLND. (4) Local or distant recurrence post-RC as assessed by CT or MRI and/or biopsy. (5) Death from any cause. | Up to 3 years | |
Secondary | Overall survival (OS) (all cohorts) | The time from start of study treatment to date of death due to any cause. | Up to 5 years | |
Secondary | Pharmacokinetics (PK) parameter for enfortumab vedotin: Maximum concentration (Cmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | Cmax will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | PK parameter for monomethyl auristatin E (MMAE): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | Cmax will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | PK parameter for total antibody (Tab): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | Cmax will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | Incidence of antitherapeutic antibodies (ATA) to enfortumab vedotin (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | Blood samples for ATA analysis will be collected. | Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated. | |
Secondary | PK parameter for enfortumab vedotin: Time to maximum concentration (Tmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | Tmax will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | PK parameter for MMAE: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | Tmax will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | PK parameter for Tab: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | Tmax will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | PK parameter for enfortumab vedotin: Area under the concentration-time curve (AUC) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | AUC will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | PK parameter for MMAE: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | AUC will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | PK parameter for Tab: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) | AUC will be derived from the PK blood samples collected. | Through 2 cycles of treatment, up to 42 days | |
Secondary | Pathologic downstaging (pDS) rate by central pathology review (MIBC cohorts only) | The pDS rate is defined as patients with tumors Up to approximately 5 months |
| |
Secondary | Disease-free survival (DFS) by investigator assessment (MIBC cohorts only) | DFS is defined as the time from RC to the time of first occurrence of a DFS event, including local recurrence of urothelial cancer (UC), urinary tract recurrence of UC, distant metastasis of UC, or death from any cause. | Up to approximately 5 years | |
Secondary | DFS by BICR (Cohort L only) | DFS is defined as the time from RC to the time of first occurrence of a DFS event | Up to 3 years | |
Secondary | Type, incidence, severity, seriousness, and relatedness of AEs (Randomized Cohort K and MIBC cohorts only) | Descriptive statistics will be used to summarize results. | Through 1 month following last dose, or end-of-treatment visit whichever is later, up to approximately 3 years | |
Secondary | Type, incidence, and severity of laboratory abnormalities (Randomized Cohort K and MIBC cohorts only) | Descriptive statistics will be used to summarize results. | Through 1 month following last dose, or end-of-treatment visit whichever is later, up to approximately 3 years | |
Secondary | Percentage of planned radical cystectomy and pelvic lymph node dissections (RC+PLND) delayed due to treatment-related AEs (MIBC cohorts only) | Delayed is defined as greater than 12 weeks after the last dose of treatment. | Up to approximately 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02612194 -
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02805608 -
uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02534623 -
Postoperative Quality of Recovery After Transurethral Resection of the Bladder
|
N/A | |
Recruiting |
NCT02228473 -
Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort
|
N/A | |
Completed |
NCT02778243 -
Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level
|
N/A | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Terminated |
NCT02560038 -
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02252445 -
Propofol and Sevoflurane for Catheter-Related Bladder Discomfort
|
N/A | |
Not yet recruiting |
NCT02760953 -
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
|
N/A | |
Terminated |
NCT04430036 -
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT06289283 -
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
|
||
Active, not recruiting |
NCT03661320 -
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
|
Phase 3 | |
Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT03404791 -
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
|
Phase 1 | |
Terminated |
NCT01479348 -
Imaging Study for FdCyd and THU Cancer Treatment
|
Early Phase 1 | |
Recruiting |
NCT05742867 -
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
|
||
Recruiting |
NCT03973671 -
Prospective Sample Collection for Cancer of Bladder
|